CVS

NYSE·Healthcare·Medical - Healthcare Plans·USA

Latest market price

107.74

+0.85+0.80%

Overview Short InterestFilings

CVSQT76CVS Health Corp.·NYSE

Overview Short InterestFilings

107.74+0.80%

News

Up 0.8% — The Big 3: GOOGL, SMCI, CVS (youtube.com).

Medium confidence

Loading chart...

Screen all →

ELV-0.43%$377.68 CI+1.15%$289.57 UNH-0.67%$420.74 HUM-1.31%$389.32 CNC-0.52%$63.41 MOH-1.37%$197.55 OSCR-2.52%$28.19 ALHC-2.85%$19.43

Snapshot

Index

S&P 500

P/E

46.64

EPS (ttm)

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-24-26	Reiterated	UBS	Buy	$115 → $122
Jul-14-26	Reiterated	Truist Securities	Buy	$108 → $118
Jul-13-26	Reiterated	Wells Fargo	Overweight	$103 → $123
Jul-09-26	Reiterated	RBC Capital	Outperform	$107 → $113
Jul-07-26	Reiterated	Cantor Fitzgerald	Overweight	$115 → $110
Jul-06-26	Reiterated	HSBC		$85 → $103
Jun-08-26	Reiterated	Mizuho	Outperform	$110 → $115
Jun-04-26	Reiterated	Morgan Stanley	Overweight	$106 → $111
Jun-01-26	Reiterated	Piper Sandler	Overweight	$101 → $113
Jun-01-26	Reiterated	Truist Securities	Buy	$102 → $108

Company

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Ownership

Total institutional ownership89.13%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	407,905	402,067	372,809	357,776	322,467	292,111	268,706	256,776	194,579
Cost of Goods Sold Incl. D&A	351,315	346,705	321,408	303,345	267,965	239,991	219,660	211,248	163,041
Gross Profit	56,590	55,362	51,401	54,431	54,502	52,120	49,046	45,528	31,538
Selling, General and Administrative Excl. Other	0	0	41,229	0	0	0	0	0	0
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	50,624	44,977	1,656	40,688	46,548	38,810	35,135	33,541	27,517
Operating Income	5,966	10,385	8,516	13,743	7,954	13,310	13,911	11,987	4,021
Interest Expense	3,108	3,119	2,958	2,658	2,287	2,503	2,907	3,035	2,619
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	599	-5,130	590	88	169	-270	-1,234	45	4
Net Income Before Taxes	3,457	2,136	6,148	11,173	5,836	10,537	9,770	8,997	1,406
Income Taxes	568	408	1,562	2,805	1,509	2,548	2,569	2,366	2,002
Consolidated Net Income	2,932	1,768	4,614	8,344	4,311	8,001	7,179	6,634	-594
Net Income From Continuing Operations	2,889	1,728	4,586	8,368	4,327	7,989	7,201	6,631	-596
Net Income	2,932	1,768	4,614	8,344	4,311	8,001	7,179	6,634	-594
EPS (Recurring)	2.31	1.40	3.66	6.49	3.29	6.00	5.48	5.10	-0.57
EPS (Basic, Before Extraordinaries)	2.31	1.40	3.66	6.49	3.29	6.00	5.48	5.10	-0.57
EPS (Diluted)	2.27	1.39	3.66	6.47	3.26	5.95	5.46	5.08	-0.57
EBITDA	11,132	9,861	13,683	18,197	12,347	17,526	17,118	16,403	6,743
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	47.46	57.09	12.27	12.20	28.59	17.34	12.51	14.62	—
Price To Sales Ratio	0.34	0.25	0.15	0.28	0.38	0.47	0.33	0.38	0.35
Gross Margin	13.87	13.77	13.79	15.21	16.90	17.84	18.25	17.73	16.21
Operating Margin	1.46	2.58	2.28	3.84	2.47	4.56	5.18	4.67	2.07
Net Margin	0.72	0.44	1.24	2.33	1.34	2.74	2.67	2.58	-0.31
Shares Outstanding	1,273	1,267	1,259	1,285	1,312	1,319	1,309	1,301	1,044
Market Capitalization	137,153	100,549	56,517	101,464	122,265	136,068	89,405	96,651	68,403
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBBINS LARRY	Director	May 21 '26	Sale	75.69	748,462	56,652,627	0	May 21
ROBBINS LARRY	Director	May 20 '26	Sale	93.82	1,018,000	95,510,822	5,195,261	May 21
ROBBINS LARRY	Director	May 19 '26	Sale	94.45	1,983,538	187,341,307	6,213,261	May 21
Mandadi Tilak	EVP, Chief Exp & Tech Officer	May 08 '26	Sale	89.58	69,551	6,230,379	10,133	May 11
Nelson Steven H	EVP and President, Aetna	Jan 23 '25	Buy	53.70	24	1,289	24	Jan 27
CAPOZZI HEIDI B	EVP and Chief People Officer	Oct 23 '24	Buy	56.85	35	1,990	85	Oct 14
CAPOZZI HEIDI B	EVP and Chief People Officer	Oct 02 '24	Buy	62.24	10	622	50	Oct 14
CAPOZZI HEIDI B	EVP and Chief People Officer	Sep 09 '24	Buy	56.47	35	1,976	40	Oct 14
Finucane Anne A.	Director	Aug 20 '25	Sale	71.02	7,500	532,650	22,156	Aug 29
SANSONE GUY P	Director	Jun 05 '25	Buy	63.70	1,570	100,009	12,007	Jun 09
ROBBINS LARRY	Director	May 06 '25	Sale	66.67	150,000	10,000,710	8,196,799	May 06
ROBBINS LARRY	Director	May 05 '25	Sale	67.41	1,323,932	89,249,945	8,346,799	May 06
ROBBINS LARRY	Director	May 02 '25	Sale	67.86	2,276,068	154,444,758	9,670,731	May 06
Shah Prem S	EVP and Group President	Mar 17 '25	Option Exercise	62.21	846	52,630	43,190	Mar 18
Clark James David	SVP, Cont & Chief Acct Officer	Mar 05 '25	Option Exercise	62.21	7,513	467,384	15,907	Mar 07


Market Cap	137.47B	Forward P/E	12.79	EPS next Y	8.42	Insider Trans	-22.04%	Shs Float	1.27B	Perf Month	5.76%


Enterprise Value	206.27B	PEG	-	EPS next Q	-	Inst Own	89.13%	Short Float	1.53%	Perf Quarter	36.62%


Income	2.94B	P/S	0.34	EPS this Y	227.83%	Inst Trans	-	Short Ratio	2.35	Perf Half Y	30.31%


Sales	407.89B	P/B	1.77	EPS next Y	13.20%	ROA	1.16%	Short Interest	19.52M	Perf YTD	35.76%


Book/sh	-	P/C	13.27	EPS next 5Y	13.15%	ROE	3.87%	52W High	110.68 -2.66%	Perf Year	74.20%


Cash/sh	-	P/FCF	18.59	EPS past 3/5Y	-24.73% -23.94%	ROIC	2.91%	52W Low	58.50 84.17%	Perf 3Y	44.85%


Dividend Est.	2.66 (2.47%)	EV/EBITDA	18.53	Sales past 3/5Y	7.63% 8.39%	Gross Margin	13.87%	Volatility	2.02% 2.28%	Perf 5Y	31.84%


Dividend TTM	2.66 (2.47%)	EV/Sales	0.51	EPS Y/Y TTM	-37.98%	Oper. Margin	1.46%	ATR (14)	2.48	Perf 10Y	10.55%


Dividend Ex-Date	Jul 23, 2026	Quick Ratio	0.66	Sales Y/Y TTM	9.41%	Profit Margin	0.72%	RSI (14)	61.42	Recom	2.10


Dividend Gr. 3/5Y	6.53% 5.87%	Current Ratio	0.87	EPS Q/Q	14.22%	SMA20	2.04%	Beta	0.58	Target Price	107.60


Payout	116.10%	Debt/Eq	1.01	Sales Q/Q	6.17%	SMA50	7.64%	Rel Volume	0.65	Prev Close	106.89


Employees	300,000	LT Debt/Eq	1.16	Earnings	Aug 05	SMA200	28.49%	Avg Volume	8.28M	Price	107.74


IPO Date	Feb 21, 1973	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.70% 5.72%	Net Debt/EBITDA	6.18	Volume	5,368,017	Change	0.80%